Stress could activate ‘crosstalking’ cell signals that turn body’s natural wound healing process against it
Stress could activate ‘crosstalking’ cell signals that decrease the body’s natural healing process after a wound occurs, according to a new study released today in STEM CELLS Translational Medicine. The finding helps explain how stress impairs healing and, conversely, could lead to a way to overcome chronic wounds resulting from serious burns and other skin injuries.
Lower starting doses of sorafenib feasible for advanced thyroid cancer
A new study published in The Oncologistjournal shows that a subset of patients with advanced differentiated thyroid cancer (DTC) and multiple comorbidities in which full-dose sorafenib is considered unsafe can initiate treatment with sorafenib at lower starting doses without adversely affecting efficacy or tolerability compared with full-dose sorafenib. A team of researchers led by Ramona Dadu, MD, at the MD Anderson Cancer Center in Houston, TX, performed a retrospective analysis to evaluate the relationship between sorafenib starting doses and first-line treatment tolerability and efficacy.
First study tracking stem cell treatments for children with spinal cord injuries shows potential benefit
Previous studies have shown that multiple stem cell implantations might assist adults suffering from complete spinal cord injuries (SCI). Now a groundbreaking study released today in STEM CELLS Translational Medicine shows for the first time that children with SCI might benefit, too.
PET/CT and biomarkers predict treatment response in metastatic colon cancer
A new study published online today in The Oncologist journal shows that an assessment of metabolic response in patients with metastatic colon cancer (mCC) treated with a single course of chemotherapy could predict the downstream efficacy of the treatment. A team of researchers from various institutions in Denmark, led by Bodil Engelmann, MD, at Næstved Hospital in Copenhagen, performed a prospective, monocentric study to determine the predictive value of a number of established biomarkers as well as the results of 2-deoxy-2-[18F]fluoro-D-glucose (FDG) positron-emission tomography/computed tomography (PET/CT) in the early response of mCC to treatment with widely used chemotherapeutic drugs.
Diabetes drug improves outcomes for cancer patients
November 20, 2013 - A new study published online in The Oncologist journal shows that cancer patients with concurrent type 2 diabetes treated with metformin have a greater overall survival rate compared with patients taking other glucose-lowering medications. A team of researchers led by Ming Yin, MD, at Geisinger Medical Center in Danville, PA, performed a meta-analysis to evaluate the association of metformin treatment and both overall and cancer-specific survival.
Page 1 of 2